ENG/中
美国
老虎证券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登录
立即注册
Toggle
美股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
美国抗疫概念
1,334.78
-7.0070
-0.52%
涨家数:
6
跌家数:
14
平家数:
- -
市盈率:
- -
高:
1,347.58
开:
1,341.87
低:
1,324.07
收:
1,341.78
数据加载中...
总览
新闻
【东方生物:获新冠/甲乙流/合胞病毒/腺病毒抗原联合检测试剂境外医疗器械注册证】金融界4月16日消息,东方生物近日取得 COVID-19/Flu A&B/RSV/Adeno Ag Combo Rapid Test Cassette (Swab)(新冠/甲乙流/合胞病毒/腺病毒抗原联合检测试剂(胶体金法))的境外医疗器械注册证,证书编号为 6188440TD01,预期用途为用于定性检测鼻拭子中相关病毒标本,帮助快速鉴别诊断呼吸系统相关病毒的感染,有效期为 2025/4/15 - 2030/4/1。上述产品取得欧盟 CE 认证,有利于整体市场拓展,但产品的实际销售业绩取决于实际竞争力和市场销售能力,目前无法预测对公司未来经营业绩的影响。
金融界
·
04-16
辉瑞被减肥药“搞怕了”
Ofweek维科网
·
04-16
辉瑞4月15日成交额为11.68亿美元
市场透视
·
04-16
莫德纳4月15日成交额为1.84亿美元
市场透视
·
04-16
阿斯利康4月15日成交额为4.00亿美元
市场透视
·
04-16
雅培4月15日成交额为10.91亿美元
市场透视
·
04-16
辉瑞因潜在肝脏损伤停止减肥药测试Pfizer Ends Testing of Obesity Pill After Possible Liver Injury
动脉网
·
04-16
诺瓦瓦克斯医药盘中异动 股价大跌5.07%
市场透视
·
04-16
【LVMH集团跌超7%,在欧股“十一罗汉”中表现最差,并领跌一众奢侈品概念股】周二,阿斯麦控股荷兰阿姆斯特丹股价收涨2.61%,报605.40欧元。诺和诺德哥本哈根股价收跌2.34%,报425.70。LVMH集团收跌7.82%,欧莱雅跌2%,阿斯利康和赛诺菲至多跌0.39%,雀巢则收涨0.38%,罗氏、诺华、德国思爱普Sap、葛兰素史克至多涨1.78%。欧洲奢侈品概念股中,除了路易威登母公司LVMH集团之外,开云集团跌5.22%,博柏利跌4.55%,人头马君度、保乐力加、雨果博斯、斯沃琪集团、瑞士历峰集团跌3.69%-0.88%,爱马仕则收涨0.21%。
金融界
·
04-16
Nanoviricides, Inc.盘中异动 股价大涨5.04%报1.25美元
市场透视
·
04-16
Ocugen, Inc.盘中异动 早盘急速拉升5.75%
市场透视
·
04-15
Co-Diagnostics, Inc.盘中异动 早盘大幅跳水6.21%报0.340美元
市场透视
·
04-15
美国疾病预防控制中心顾问讨论缩小 COVID-19 强化疫苗的使用范围
路透中文
·
04-15
1名受试者出现肝损伤,辉瑞终止一款口服减肥药临床开发,死磕小分子GLP-1
时代财经
·
04-15
美国疾病预防控制中心顾问将在拖延数月后审查疫苗指南
路透中文
·
04-15
在美销售额占三成 这家HMB供应商IPO提交注册
证券市场周刊
·
04-15
辉瑞(PFE.US)研发受挫引发收购猜测 减肥药新贵股价大涨
智通财经
·
04-15
辉瑞又双叒叕放弃一款口服 GLP-1,肥胖管线仅剩 1 款药物
Insight数据库
·
04-15
辉瑞4月14日成交额为13.66亿美元
市场透视
·
04-15
辉瑞的GLP失败了
生物药大时代
·
04-15
更多
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK4568/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美国抗疫概念","latestPrice":1334.7778,"timestamp":1745265599999,"preClose":1341.7848,"halted":0,"volume":71946039,"delay":0,"changeRate":-0.005222,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-7.006958,"latestTime":"04-21 16:00:00 EDT","open":1341.8679,"high":1347.5837,"low":1324.0696,"amount":3662138493.360566,"amplitude":0.017525,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.67431,"peRate":24.399045,"turnoverRate":0.004637,"increases":6,"decrements":14,"flats":0,"marketCap":1102654190744,"floatMarketCap":1083305764892},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1347.5837,"amplitude":0.017525,"preClose":1341.7848,"low":1324.0696,"pbRate":"3.67431","latestPrice":1334.7778,"volume":71946039,"delay":0,"open":1341.8679,"prevYearClose":1274.8187,"prevWeekClose":1341.7848,"prevMonthClose":1427.887,"prevQuarterClose":1427.887,"fiveDayClose":1308.2719,"twentyDayClose":1415.9906,"sixtyDayClose":1315.7013,"secType":"PLATE","market":"US","turnoverRate":0.004637,"peRate":24.399045,"marketCap":1102654190744,"floatMarketCap":1083305764892,"timestamp":1745265599999,"nameCN":"美国抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":6,"down":14,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527268899","title":"【东方生物:获新冠/甲乙流/合胞病毒/腺病毒抗原联合检测试剂境外医疗器械注册证】金融界4月16日消息,东方生物近日取得 COVID-19/Flu A&B/RSV/Adeno Ag Combo Rapid Test Cassette (Swab)(新冠/甲乙流/合胞病毒/腺病毒抗原联合检测试剂(胶体金法))的境外医疗器械注册证,证书编号为 6188440TD01,预期用途为用于定性检测鼻拭子中相关病毒标本,帮助快速鉴别诊断呼吸系统相关病毒的感染,有效期为 2025/4/15 - 2030/4/1。上述产品取得欧盟 CE 认证,有利于整体市场拓展,但产品的实际销售业绩取决于实际竞争力和市场销售能力,目前无法预测对公司未来经营业绩的影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527268899","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527268899?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 16:45","pubTimestamp":1744793122,"startTime":"0","endTime":"0","summary":"金融界4月16日消息,东方生物近日取得 COVID-19/Flu A&B/RSV/Adeno Ag Combo Rapid Test Cassette (Swab)(新冠/甲乙流/合胞病毒/腺病毒抗原联合检测试剂(胶体金法))的境外医疗器械注册证,证书编号为 6188440TD01,预期用途为用于定性检测鼻拭子中相关病毒标本,帮助快速鉴别诊断呼吸系统相关病毒的感染,有效期为 2025/4/15 - 2030/4/1。上述产品取得欧盟 CE 认证,有利于整体市场拓展,但产品的实际销售业绩取决于实际竞争力和市场销售能力,目前无法预测对公司未来经营业绩的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/16164549583370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09996","BNTX","BK0239","BK1222","BK4139","09997","688298","BK1583","BK4548","BK4585","BK1574","BK4551","BK4588","CE","BK1100","159883","BK4109","BK4535","BK4568"],"gpt_icon":0},{"id":"2527123178","title":"辉瑞被减肥药“搞怕了”","url":"https://stock-news.laohu8.com/highlight/detail?id=2527123178","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527123178?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 13:53","pubTimestamp":1744782824,"startTime":"0","endTime":"0","summary":"辉瑞决定取消Danuglipron的研发,核心原因在于,有1名患者可能受到药物诱导的肝损伤。2023年末,辉瑞公布Danuglipron治疗肥胖2b期临床的最新数据。市场认为,辉瑞遭遇打击之后,可能会继续收购减肥药资产,属于Viking们的机会来了。辉瑞并没有彻底放弃减肥药资产,目前其布局的管线中,一种口服小分子GIPR拮抗剂,处于2期开发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041613534694d70573&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041613534694d70573&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0289739699.SGD","LU0122379950.USD","LU1066053197.SGD","IE00BBT3K403.USD","SG9999011175.SGD","LU0456855351.SGD","LU1023059063.AUD","LU0868494617.USD","BK4568","LU1057294990.SGD","SG9999013999.USD","BK4533","PFE","BK4581","IE00B19Z3B42.SGD","SG9999001176.SGD","LU0170899867.USD","BK4585","LU0234572021.USD","LU0321505868.SGD","LU1894683348.USD","IE0002270589.USD","BK4007","LU1066051498.USD","LU1894683264.USD","BK4599","SG9999003800.SGD","LU0225771236.USD","LU1883839398.USD","LU0321505439.SGD","IE000M9KFDE8.USD","BK4534","LU0225284248.USD","BK4588","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4592","LU0306806265.USD","IE00B19Z3581.USD","SG9999002232.USD","LU0306807586.USD","IE00BLSP4239.USD","BK4550","SG9999001176.USD","LU0058720904.USD","LU0985481810.HKD","SG9999002224.SGD"],"gpt_icon":1},{"id":"2527288993","title":"辉瑞4月15日成交额为11.68亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527288993","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527288993?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 10:13","pubTimestamp":1744769630,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日,辉瑞成交额为11.68亿美元,成交额较昨日减少14.48%,当日成交量为5181.47万股。辉瑞于2025年4月15日涨1.45%,报22.44美元,该股过去5个交易日涨2.75%,年初至今跌14.02%,过去60日跌13.26%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-04-15|11.68亿|-14.48%|5181.47万|#|2025-04-14|13.66亿|14.34%|6190.09万|#|2025-04-11|11.95亿|-24.16%|5507.81万|#|2025-04-10|15.75亿|-24.50%|7296.07万|#|2025-04-09|20.87亿|30.20%|9595.44万|辉瑞是全球最大的制药公司之一,年销售额接近500亿美元。辉瑞在全球销售这些产品,国际销售额占其总销售额的近50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416101358a45a7557&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416101358a45a7557&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456855351.SGD","BK4599","LU0225771236.USD","LU0985481810.HKD","SG9999003800.SGD","SG9999013999.USD","LU0234572021.USD","IE0002270589.USD","SG9999011175.SGD","BK4581","IE000M9KFDE8.USD","LU0170899867.USD","SG9999001176.SGD","BK4568","LU0321505439.SGD","LU0058720904.USD","LU1894683264.USD","LU0225284248.USD","BK4592","LU1894683348.USD","BK4550","IE00BLSP4452.SGD","IE00BLSP4239.USD","LU0306806265.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU1023059063.AUD","BK4585","PFE","LU1066053197.SGD","LU1057294990.SGD","LU0306807586.USD","SGXZ57979304.SGD","LU0122379950.USD","LU1883839398.USD","BK4007","IE00B19Z3581.USD","BK4588","BK4534","LU0321505868.SGD","SG9999002232.USD","SG9999001176.USD","LU0868494617.USD","BK4533","LU1066051498.USD","SG9999002224.SGD","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2527605407","title":"莫德纳4月15日成交额为1.84亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527605407","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527605407?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 09:58","pubTimestamp":1744768705,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日,莫德纳成交额为1.84亿美元,成交额较昨日增加6.24%,当日成交量为703.59万股。莫德纳于2025年4月15日跌2.09%,报26.24美元,该股过去5个交易日涨6.49%,年初至今跌36.89%,过去60日跌22.96%。截至 2024年9月,莫德纳拥有处于临床试验中的40个mRNA开发候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416095835a45a6fa5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416095835a45a6fa5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4551","BK4568","BK4533","BK4588","BK4534","BK4501","MRNA","BK4548","BK4585","BK4532"],"gpt_icon":0},{"id":"2527099664","title":"阿斯利康4月15日成交额为4.00亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527099664","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527099664?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 09:16","pubTimestamp":1744766191,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日,阿斯利康成交额为4.00亿美元,成交额较昨日减少0.55%,当日成交量为589.09万股。阿斯利康于2025年4月15日跌0.21%,报67.87美元,该股过去5个交易日涨4.58%,年初至今涨5.04%,过去60日涨3.33%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-04-15|4.00亿|-0.55%|589.09万|#|2025-04-14|4.03亿|6.26%|593.99万|#|2025-04-11|3.79亿|-40.10%|576.15万|#|2025-04-10|6.33亿|-23.99%|976.31万|#|2025-04-09|8.32亿|-17.88%|1303.84万|1999 年,瑞典阿斯特拉公司与英国捷利康集团合并,成立了阿斯利康公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416091646a6bbe078&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416091646a6bbe078&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU2462157665.USD","BK4568","AZN","LU2456880835.USD","LU2236285917.USD","BK4588","LU0320765992.SGD","LU2417539215.USD","BK4007","LU1829250122.USD","BK4585","LU0889565916.HKD"],"gpt_icon":0},{"id":"2527604409","title":"雅培4月15日成交额为10.91亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527604409","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527604409?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 09:15","pubTimestamp":1744766114,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日,雅培成交额为10.91亿美元,成交额较昨日增加22.13%,当日成交量为863.94万股。雅培于2025年4月15日跌0.9%,报126.22美元,该股过去5个交易日涨2.3%,年初至今涨12.69%,过去60日涨11.74%。雅培约 60% 的销售额来自美国以外地区。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416091529a6bbdff2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416091529a6bbdff2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1061106388.HKD","LU1057294990.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4585","BK4592","SG9999002224.SGD","BK4082","BK4568","LU2237957811.SGD","IE00BFTCPJ56.SGD","LU0122379950.USD","BK4581","LU1721429402.USD","LU1989763427.SGD","SG9999004303.SGD","BK4504","LU1721429741.USD","LU1989763690.USD","LU2112291526.USD","BK4566","LU0234572021.USD","LU0266013472.USD","IE0002141913.USD","SG9999002232.USD","SGXZ23171101.USD","LU0170899867.USD","LU1023059063.AUD","IE0009355771.USD","LU1691799644.USD","IE00BJT1NW94.SGD","BK4533","LU1914381329.SGD","LU2089984988.USD","LU2133065610.SGD","LU2237957902.USD","LU0868494617.USD","LU2468319806.SGD","BK4588","ABT","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2527425919","title":"辉瑞因潜在肝脏损伤停止减肥药测试Pfizer Ends Testing of Obesity Pill After Possible Liver Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2527425919","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527425919?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 01:35","pubTimestamp":1744738500,"startTime":"0","endTime":"0","summary":"Pfizer will now stop all testing of danuglipron, including its use with other drugs for obesity treatment. However, the company said it still plans to work on other obesity treatments that are in earlier stages of research.辉瑞将停止对丹纳格列波隆的所有测试,包括其与其他药物联合用于肥胖症治疗的测试。Even with recent price cuts, many of these medications still cost hundreds of dollars per month.即使近期价格有所下调,许多此类药物每月的费用仍高达数百美元。Pfizer had already stopped testing of a twice-daily version of danuglipron in late 2023 after more than half the people in a trial stopped taking it.辉瑞公司已于 2023 年底停止了每日两次服用的丹那列普隆的测试,当时试验中超过一半的人已停止服用该药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1894683348.USD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0985481810.HKD","LU0306806265.USD","LU0321505439.SGD","LU1057294990.SGD","LU1066051498.USD","LU0225284248.USD","BK4599","LU0321505868.SGD","BK4568","LU1066053197.SGD","LU1894683264.USD","PFE","SG9999013999.USD","LU0170899867.USD","BK4581","IE00BBT3K403.USD","LU0122379950.USD","LU0234572021.USD","BK4550","BK4534","BK4592","SG9999002232.USD","LU0868494617.USD","LU1883839398.USD","BK4533","SG9999003800.SGD","LU0289739699.SGD","IE0002270589.USD","IE00BLSP4239.USD","LU0058720904.USD","BK4585","LU0306807586.USD","SG9999001176.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","SG9999011175.SGD","LU1023059063.AUD","LU0225771236.USD","BK4007","BK4588","SG9999002224.SGD","LU0456855351.SGD"],"gpt_icon":1},{"id":"2527428719","title":"诺瓦瓦克斯医药盘中异动 股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527428719","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527428719?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 00:56","pubTimestamp":1744736177,"startTime":"0","endTime":"0","summary":"北京时间2025年04月16日00时56分,诺瓦瓦克斯医药股票出现波动,股价大幅跳水5.07%。截至发稿,该股报6.09美元/股,成交量187.75万股,换手率1.17%,振幅7.64%。机构评级方面,在所有7家参与评级的机构中,57%的券商给予买入建议,29%的券商给予持有建议,14%的券商给予卖出建议。诺瓦瓦克斯医药股票所在的生物技术行业中,整体跌幅为0.57%。诺瓦瓦克斯医药公司简介:诺瓦瓦克斯医药公司是一家从事疫苗开发的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416005617a6bb7ba9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416005617a6bb7ba9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4547","NVAX","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2527284114","title":"【LVMH集团跌超7%,在欧股“十一罗汉”中表现最差,并领跌一众奢侈品概念股】周二,阿斯麦控股荷兰阿姆斯特丹股价收涨2.61%,报605.40欧元。诺和诺德哥本哈根股价收跌2.34%,报425.70。LVMH集团收跌7.82%,欧莱雅跌2%,阿斯利康和赛诺菲至多跌0.39%,雀巢则收涨0.38%,罗氏、诺华、德国思爱普Sap、葛兰素史克至多涨1.78%。欧洲奢侈品概念股中,除了路易威登母公司LVMH集团之外,开云集团跌5.22%,博柏利跌4.55%,人头马君度、保乐力加、雨果博斯、斯沃琪集团、瑞士历峰集团跌3.69%-0.88%,爱马仕则收涨0.21%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527284114","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527284114?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 00:54","pubTimestamp":1744736061,"startTime":"0","endTime":"0","summary":"周二,阿斯麦控股荷兰阿姆斯特丹股价收涨2.61%,报605.40欧元。诺和诺德哥本哈根股价收跌2.34%,报425.70。LVMH集团收跌7.82%,欧莱雅跌2%,阿斯利康和赛诺菲至多跌0.39%,雀巢则收涨0.38%,罗氏、诺华、德国思爱普Sap、葛兰素史克至多涨1.78%。欧洲奢侈品概念股中,除了路易威登母公司LVMH集团之外,开云集团跌5.22%,博柏利跌4.55%,人头马君度、保乐力加、雨果博斯、斯沃琪集团、瑞士历峰集团跌3.69%-0.88%,爱马仕则收涨0.21%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/16005449565332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00BD6J9T35.USD","LU0823434583.USD","LRLCY","BK4202","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4212","LVMUY","IE00BKVL7J92.USD","BK4585","LU2063271972.USD","BK4007","LU2417539215.USD","LU0345774631.USD","BK4568","LU0070302665.USD","IE00BFTCPJ56.SGD","NVS","LU0823434740.USD","LU0345774391.USD","GSK","BK4532","BK4543","NSRGY","LU2236285917.USD","03165","LU0320765489.SGD","IE0002141913.USD","BK4599","AZN","BK4147","LU0211331839.USD","LU0154236417.USD","LU0320765992.SGD","LU1093756325.SGD","LU0097036916.USD","IE0004445239.USD","IE0009355771.USD","IE00BZ1G4Q59.USD","LU2456880835.USD","IE00BJT1NW94.SGD","GSK.UK","BK4578","LU0889565916.HKD","BK4588","LU0208291251.USD","LU2462157665.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2527447082","title":"Nanoviricides, Inc.盘中异动 股价大涨5.04%报1.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527447082","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527447082?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 00:02","pubTimestamp":1744732978,"startTime":"0","endTime":"0","summary":"北京时间2025年04月16日00时02分,Nanoviricides, Inc.股票出现异动,股价急速拉升5.04%。Nanoviricides, Inc.股票所在的生物技术行业中,整体跌幅为0.25%。其相关个股中,Mural Oncology Plc、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Skye Bioscience, Inc.涨幅较大,Mural Oncology Plc、Dogwood Therapeutics, Inc.、Metavia Inc.较为活跃,换手率分别为1272.94%、906.96%、242.36%,振幅较大的相关个股有Skye Bioscience, Inc.、Mural Oncology Plc、Dogwood Therapeutics, Inc.,振幅分别为171.53%、97.08%、91.33%。Nanoviricides, Inc.公司简介:Nanoviricides Inc是一家纳米生物制药公司,致力于发现、开发和商业化治疗剂,以推进对患有危及生命的病毒感染患者的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041600025894d64b43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041600025894d64b43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","NNVC","BK4139"],"gpt_icon":0},{"id":"2527410402","title":"Ocugen, Inc.盘中异动 早盘急速拉升5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527410402","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527410402?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 21:51","pubTimestamp":1744725114,"startTime":"0","endTime":"0","summary":"北京时间2025年04月15日21时51分,Ocugen, Inc.股票出现异动,股价快速上涨5.75%。Ocugen, Inc.股票所在的生物技术行业中,整体涨幅为0.22%。其相关个股中,Mural Oncology Plc、Prokidney Corp.、Verve Therapeutics, Inc.涨幅较大,Mural Oncology Plc、Metavia Inc.、Plus Therapeutics, Inc.较为活跃,换手率分别为609.31%、216.04%、86.39%,振幅较大的相关个股有60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Mural Oncology Plc、Nextcure, Inc.,振幅分别为80.08%、66.02%、38.78%。Ocugen, Inc.公司简介:Ocugen Inc公司专注于发现、开发和商业化新型基因和细胞疗法以及疫苗,旨在改善健康并为全球患者带来希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504152151549738aad9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504152151549738aad9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4139","OCGN","BK4563"],"gpt_icon":0},{"id":"2527792412","title":"Co-Diagnostics, Inc.盘中异动 早盘大幅跳水6.21%报0.340美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527792412","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527792412?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 21:36","pubTimestamp":1744724214,"startTime":"0","endTime":"0","summary":"北京时间2025年04月15日21时36分,Co-Diagnostics, Inc.股票出现异动,股价大幅跳水6.21%。截至发稿,该股报0.340美元/股,成交量1600股,换手率0.01%,振幅0.00%。Co-Diagnostics, Inc.股票所在的医疗器械行业中,整体涨幅为0.10%。其相关个股中,Dih Holdings Us Inc C/Wts 20/04/2028 、Biomerica, Inc.、Strata Skin Sciences, Inc.涨幅较大,Venus Concept Inc.、Bluejay Diagnostics, Inc.、Reshape Lifesciences, Inc.较为活跃,换手率分别为7.69%、6.53%、4.18%,振幅较大的相关个股有Inspira Technologies Oxy B.H.N. Ltd.、Dih Holding Us, Inc.、Neuropace, Inc.,振幅分别为11.23%、8.28%、7.40%。Co-Diagnostics, Inc.公司简介:Co-Diagnostics Inc是一家分子诊断公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504152136549738a6e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504152136549738a6e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CODX","BK4568","BK4082"],"gpt_icon":0},{"id":"2527145754","title":"美国疾病预防控制中心顾问讨论缩小 COVID-19 强化疫苗的使用范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2527145754","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527145754?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 21:21","pubTimestamp":1744723292,"startTime":"0","endTime":"0","summary":"更新版 3-美国疾病预防控制中心顾问讨论缩小 COVID-19 强化疫苗的使用范围正在审查 2025-2026 年接种 COVID 疫苗的建议专家小组讨论了仅为易感人群接种 COVID 疫苗的建议专家将在 6 月会议上提出建议与 COVID 疫苗讨论一起重新编排第 1-5 段,在第 7 和第 11 段中添加分析师意见Mariam Sunny/Sneha S K. 路透4月15日 - 周二,美国疾病控制和预防中心的疫苗专家外部小组在特朗普新政府执政后的首次会议上讨论了缩小 COVID-19 强化疫苗使用范围的建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL4T3QT16I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","NVAX","BK4568","BK4547","BK4139","BK4588"],"gpt_icon":0},{"id":"2527499611","title":"1名受试者出现肝损伤,辉瑞终止一款口服减肥药临床开发,死磕小分子GLP-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499611","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499611?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 18:55","pubTimestamp":1744714542,"startTime":"0","endTime":"0","summary":"一款口服减重药折戟。图片来源:图虫创意跨国药企辉瑞又终止一款口服GLP-1R激动剂的临床开发。时代财经从辉瑞获悉,美国时间4月14日,辉瑞宣布决定终止开发每日一次的口服GLP-1R激动剂Danuglipron,该药物用于减重管理。由于安全性问题待解,辉瑞经多方考虑后选择终止开发这一小分子药物。而在Danuglipron之前,早在2023年6月,辉瑞就终止了其旗下另一款GLP-1R小分子激动剂项目Lotiglipron的后续研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415185615973879d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415185615973879d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456855351.SGD","LU0306807586.USD","LU1066051498.USD","LU0985481810.HKD","SG9999011175.SGD","BK4144","IE00BLSP4452.SGD","BK4585","BK4599","LU1894683264.USD","LU1057294990.SGD","SG9999001176.USD","BK4590","SGXZ57979304.SGD","GLP","IE00BBT3K403.USD","LU1894683348.USD","BK4581","BK4533","BK4534","BK4588","LU0306806265.USD","IE00B19Z3B42.SGD","LU1883839398.USD","SG9999001176.SGD","BK4007","LU0225284248.USD","LU0868494617.USD","IE00B19Z3581.USD","SG9999013999.USD","IE000M9KFDE8.USD","BK4550","IE00BLSP4239.USD","IE0002270589.USD","LU0225771236.USD","LU1066053197.SGD","LU0321505439.SGD","LU0234572021.USD","SG9999002224.SGD","LU0170899867.USD","LU0289739699.SGD","BK4568","SG9999003800.SGD","LU1023059063.AUD","LU0122379950.USD","PFE","BK4592","SG9999002232.USD","LU0321505868.SGD","LU0058720904.USD"],"gpt_icon":1},{"id":"2527608184","title":"美国疾病预防控制中心顾问将在拖延数月后审查疫苗指南","url":"https://stock-news.laohu8.com/highlight/detail?id=2527608184","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527608184?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 18:00","pubTimestamp":1744711242,"startTime":"0","endTime":"0","summary":"美国疾病预防控制中心顾问将在拖延数月后审查疫苗指南会议因肯尼迪被任命为卫生部长而推迟 专家小组讨论 RSV 和基孔肯雅疫苗的指导方针正在审查 2025-2026 年接种 COVID 疫苗的建议Mariam Sunny/Sneha S K. 路透4月15日 - 美国疾病控制和预防中心的外部专家小组在推迟近两个月后将于周二召开会议,预计将审查几种疫苗的指导方针,包括对下一代 COVID-19 疫苗的建议。肯尼迪否认 \"反疫苗\",并表示他不会阻止美国人接种疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL4S3QT0U2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4547","NVAX","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2527462257","title":"在美销售额占三成 这家HMB供应商IPO提交注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2527462257","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527462257?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 16:25","pubTimestamp":1744705500,"startTime":"0","endTime":"0","summary":"全球最大的HMB供应商即将上市,核心产品市场份额稳定。4月3日, IPO企业技源集团股份有限公司通过了上市委会议,目前提交了注册。同期内,技源集团的氨糖产品销量分别为1874.41吨、2750.08吨和2590.54吨。据招股书披露,雅培集团是技源集团HMB业务的主要客户之一,报告期各期,技源集团向雅培集团的销售收入占主营业务收入的比例分别为 23.44%、17.38%和19.44%,占公司HMB业务收入的比例分别为69.26%、64.69%和66.19%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-04-15/doc-inetfxpw1048028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4082","LU2237957902.USD","BK4566","LU1023059063.AUD","LU1057294990.SGD","BK4533","LU1061106388.HKD","LU1989763690.USD","IE0002141913.USD","SG9999002232.USD","IE00B2B36J28.USD","LU0122379950.USD","BK4581","BK4568","LU2089984988.USD","SG9999002224.SGD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0170899867.USD","LU2112291526.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU1691799644.USD","LU0234572021.USD","IE00B4R5TH58.HKD","LU0868494617.USD","BK4504","SG9999004303.SGD","BK4588","LU1914381329.SGD","LU1721429741.USD","IE00BJJMRZ35.SGD","LU2237957811.SGD","LU2133065610.SGD","BK4592","SGXZ23171101.USD","LU1721429402.USD","LU1989763427.SGD","BK4585","LU0266013472.USD","ABT"],"gpt_icon":0},{"id":"2527745364","title":"辉瑞(PFE.US)研发受挫引发收购猜测 减肥药新贵股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2527745364","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527745364?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 15:04","pubTimestamp":1744700695,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,辉瑞停止开发备受关注的口服减肥药Danuglipron,投资者押注这一挫折可能会刺激辉瑞寻求并购交易,几家开发减肥药的生物技术公司股价周一上涨。辉瑞此前表示,将停止开发备受关注的口服减肥药Danuglipron,因为一名参加临床试验的患者出现了潜在的药物性肝损伤。辉瑞一直试图与诺和诺德和礼来在减肥治疗市场竞争,但该公司在研发减肥药物方面已经落后于竞争对手。Danuglipron研发终止可能会使辉瑞的产品组合出现缺口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0306806265.USD","LU1023059063.AUD","LU0985481810.HKD","LU0289739699.SGD","LU1883839398.USD","SG9999003800.SGD","LU1057294990.SGD","BK4533","PFE","IE00BBT3K403.USD","IE00B19Z3581.USD","SG9999002232.USD","LU0122379950.USD","BK4581","BK4599","BK4568","SG9999002224.SGD","LU0456855351.SGD","LU0225771236.USD","LU0058720904.USD","LU0170899867.USD","IE00BLSP4452.SGD","SG9999001176.SGD","BK4550","BK4534","LU0321505439.SGD","LU0234572021.USD","LU0306807586.USD","SG9999013999.USD","LU1066053197.SGD","LU0868494617.USD","BK4007","LU1066051498.USD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","LU1894683264.USD","BK4588","LU0321505868.SGD","IE0002270589.USD","LU1894683348.USD","SG9999011175.SGD","BK4592","IE000M9KFDE8.USD","SGXZ57979304.SGD","SG9999001176.USD","BK4585","LU0225284248.USD"],"gpt_icon":1},{"id":"2527341315","title":"辉瑞又双叒叕放弃一款口服 GLP-1,肥胖管线仅剩 1 款药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2527341315","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527341315?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 11:45","pubTimestamp":1744688751,"startTime":"0","endTime":"0","summary":"当地时间 4 月 14 日,辉瑞宣布终止开发口服胰高血糖素样肽-1受体激动剂 Danuglipron。安慰剂校正后,32 周时平均体重下降 8% 至 13%,26 周时平均体重下降 5% 至 9.5%。然而此次出现的潜在肝损伤病例,每日一次的Danuglipron 也终被辉瑞放弃。Danuglipron 并不是辉瑞在肥胖领域首次折戟的药物。在先后终止 Lotiglipron 和Danuglipron 开发后,目前辉瑞的肥胖药物管线仅剩一款口服 GIPR 拮抗剂PF-07976016,全球最高状态处于临床 II 期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415200413a459a994&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415200413a459a994&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU0456855351.SGD","LU0985481810.HKD","BK4007","SG9999013999.USD","IE00BLSP4239.USD","BK4581","LU0234572021.USD","LU1894683348.USD","BK4592","SG9999011175.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU0306806265.USD","BK4534","LU1894683264.USD","LU0170899867.USD","IE00B19Z3581.USD","BK4590","LU0225284248.USD","LU0321505439.SGD","SG9999002224.SGD","LU0321505868.SGD","LU1066051498.USD","LU1023059063.AUD","BK4533","SG9999001176.USD","IE00B19Z3B42.SGD","SG9999003800.SGD","LU0289739699.SGD","LU0868494617.USD","PFE","LU0058720904.USD","IE0002270589.USD","LU0306807586.USD","BK4588","BK4144","LU0225771236.USD","BK4568","IE000M9KFDE8.USD","SG9999001176.SGD","BK4550","BK4599","LU1066053197.SGD","SG9999002232.USD","LU0122379950.USD","LU1883839398.USD","GLP","LU1057294990.SGD","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2527010965","title":"辉瑞4月14日成交额为13.66亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527010965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527010965?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 10:09","pubTimestamp":1744682987,"startTime":"0","endTime":"0","summary":"美东时间2025年4月14日,辉瑞成交额为13.66亿美元,成交额较昨日增加14.34%,当日成交量为6190.09万股。辉瑞于2025年4月14日涨0.96%,报22.12美元,该股过去5个交易日跌2.25%,年初至今跌15.24%,过去60日跌15.11%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-04-14|13.66亿|14.34%|6190.09万|#|2025-04-11|11.95亿|-24.16%|5507.81万|#|2025-04-10|15.75亿|-24.50%|7296.07万|#|2025-04-09|20.87亿|30.20%|9595.44万|#|2025-04-08|16.03亿|-17.07%|7240.60万|辉瑞是全球最大的制药公司之一,年销售额接近500亿美元。辉瑞在全球销售这些产品,国际销售额占其总销售额的近50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415100950a6bab065&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415100950a6bab065&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456855351.SGD","BK4599","LU0225771236.USD","LU0985481810.HKD","SG9999003800.SGD","SG9999013999.USD","LU0234572021.USD","IE0002270589.USD","SG9999011175.SGD","BK4581","IE000M9KFDE8.USD","LU0170899867.USD","SG9999001176.SGD","BK4568","LU0321505439.SGD","LU0058720904.USD","LU1894683264.USD","LU0225284248.USD","BK4592","LU1894683348.USD","BK4550","IE00BLSP4452.SGD","IE00BLSP4239.USD","LU0306806265.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU1023059063.AUD","BK4585","PFE","LU1066053197.SGD","LU1057294990.SGD","LU0306807586.USD","SGXZ57979304.SGD","LU0122379950.USD","LU1883839398.USD","BK4007","IE00B19Z3581.USD","BK4588","BK4534","LU0321505868.SGD","SG9999002232.USD","SG9999001176.USD","LU0868494617.USD","BK4533","LU1066051498.USD","SG9999002224.SGD","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2527436727","title":"辉瑞的GLP失败了","url":"https://stock-news.laohu8.com/highlight/detail?id=2527436727","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527436727?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 09:44","pubTimestamp":1744681496,"startTime":"0","endTime":"0","summary":"4月14日,辉瑞宣布终止开发口服胰高血糖素样肽-1受体激动剂danuglipron,该药物此前正在研究用于慢性体重管理。在审查了所有信息,包括迄今为止为danuglipron生成的所有临床数据和监管机构的最新沟通后,辉瑞决定停止该分子的开发。市场对辉瑞制药撤回danuglipron的反应似乎有利于维京医疗、礼来和诺和诺德公司,因为慢性体重管理GLP-1受体激动剂领域的竞争可能会减少。因此,投资者对这些可能填补辉瑞制药退出这一药物类别留下空白的公司表现出更大兴趣。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415131247a4594490&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415131247a4594490&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4592","IE00BBT3K403.USD","LU0170899867.USD","LU0058720904.USD","BK4588","LU0868494617.USD","BK4590","LU0306806265.USD","BK4581","BK4568","LU1894683264.USD","IE00B19Z3B42.SGD","LU0122379950.USD","BK4599","LU0321505868.SGD","IE00B19Z3581.USD","LU0289739699.SGD","LU0225284248.USD","IE00BLSP4452.SGD","SG9999002224.SGD","BK4533","LU0306807586.USD","BK4585","BK4144","IE00BLSP4239.USD","LU1883839398.USD","LU1057294990.SGD","LU0234572021.USD","LU0985481810.HKD","LU1066053197.SGD","LU1023059063.AUD","SG9999003800.SGD","SG9999011175.SGD","IE000M9KFDE8.USD","IE0002270589.USD","SG9999013999.USD","BK4534","SG9999002232.USD","LU0321505439.SGD","BK4007","LU0225771236.USD","PFE","SG9999001176.USD","GLP","LU0456855351.SGD","BK4550","SG9999001176.SGD","SGXZ57979304.SGD","LU1894683348.USD","LU1066051498.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":189,"code":"91000000","status":"200"}]}}